Pharma & Biotech VC & Investment News
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Today's issue
Refine Search
Pharmaceutical
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Pharmaceutical
US biotech Actio Biosciences has raised $66 million in a series B round topport its pipeline of genetically targeted therapies, with new funding led by Regeneron Ventures and repeat backing from Deerfield Management. 19 June 2025
Biotechnology
Chinese biotech start-up BioTroy Therapeutics has raised over 200 million renminbi ($28 million) in series A financing to advance clinical trials for its experimental immunotherapy targeting CD3L1, a novel immune checkpoint aimed at tough-to-treat tumors. The company also plans to expand its early-stage pipeline and grow its Shanghai-based R&D team. 18 June 2025
Biotechnology
EY today released its 35th annual Biotech Beyond Borders Report. This finds that the biopharma industry is currently at an inflection point – grappling with a unique environment of macroeconomic uncertainty and constrained access to capital, including high interest rates, inflation, shifting regulatory policies and tariff turmoil. 18 June 2025
Pharmaceutical
Draig Therapeutics, a clinical-stage company based in Cardiff, UK, and aiming to transform the treatment of neuropsychiatric diseases, today launched from stealth having raised a total of $140 million (£107 million) in the last nine months. 18 June 2025
Biotechnology
French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical activity across both solid and blood cancers. 12 June 2025
Biotechnology
Angelini Ventures has joined a syndicate of European life sciences investors to back Elkedonia, a French biotech developing a new class of neuroplastogens to treat depression and other neuropsychiatric conditions. 11 June 2025
Biotechnology
Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. 11 June 2025
Pharmaceutical
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its first-in-class, ultra-long-acting GLP-1 receptor agonist for type 2 diabetes, alongside a move to go public on the Hong Kong Stock Exchange. 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Biotechnology
San Jose, USA-based biotech Allay Therapeutics today announced the completion of a $57.5 million Series D financing round with leading global investors. 5 June 2025
Pharmaceutical
Sweden’s Karolinska Development today revealed that its portfolio company OssDsign has carried out a directed share issue through an accelerated book-building procedure that brought the company approximately 158 million kronor ($16.5 million). 4 June 2025
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Biotechnology
US biotech Moderna has reported encouraging early-stage results from a trial of its experimental vaccine for avian influenza, just as a significant federal funding agreement was unexpectedly withdrawn. 29 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Biotechnology
Cambridge, UK-based biotech start-up Maxion Therapeutics, which is developing antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, has raised $72 million (£58 million) in a Series A financing. 17 March 2025
Biotechnology
Sutro Biopharma, a US biotechnology company, has announced significant organizational changes, including a workforce reduction of nearly 50%, a shift in its drug development focus, and leadership transitions. 14 March 2025
Biotechnology
US pre-clinical biotech start-up Montara Therapeutics, which is pioneering brain-selective therapies for CNS diseases, has announced the closing of a $20 million oversubscribed expansion of its Series Seed financing. 14 March 2025
Pharmaceutical
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Pharmaceutical
California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. 13 March 2025
Biotechnology
Harbour BioMed, a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced the launch of Élancé Therapeutics. 12 March 2025
Biotechnology
USA-based Emergent BioSolutions and Swiss vaccines firm Rocketvax have announced an agreement. 12 March 2025
Pharmaceutical
Valo Therapeutics says it has successfully secured a financing round of 19 million euros ($20.6 million), part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer. 10 March 2025
Biotechnology
Tenaya Therapeutics, a clinical-stage biotechnology company based in South San Francisco, has announced plans to raise approximately $52.5 million through a public offering. 6 March 2025
Pharmaceutical
China’s Enhua Pharma has announced a $3.5 million investment in NeuroThree Therapeutics, a biotech firm specializing in treatments for central nervous system disorders. The investment secures a 10.4% stake in the company as part of its Pre-A funding round. 6 March 2025
Biotechnology
French biopharmaceutical Osivax, which is developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, has announced the successful first close of its Series B financing, raising 10 million euros ($10.05 million) from new and existing investors. 6 March 2025
Biotechnology
UK-based Trimtech Therapeutics, a biotech harnessing targeted protein degradation (TPD) for neurodegenerative diseases, has announced the closing of its $31 million seed funding round. 5 March 2025
Pharmaceutical
Leading European venture capital firm Sofinnova Partners today announced it has raised 1.2 billion euros ($1.25 billion) across its platform of investment strategies over the past year, including more than 1 billion euros secured in the last quarter. 4 March 2025
Biotechnology
Frazier Life Sciences has launched Callio Therapeutics with $187 illion in series A funding to advance a HER2-targeted, dual-payload antibody-drug conjugate (ADC) into clinical trials. 4 March 2025
Pharmaceutical
US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare Partners (Sagard), with the news pushing its shares up 6.6% to $2.10 in pre-market activity. 3 March 2025
Biotechnology
The US President Donald Trump began his second term with a series of directives targeting the US National Institutes of Health (NIH), creating uncertainty around NIH grant funding for biopharmaceutical drug development. 1 March 2025
Biotechnology
Duality Biologics, a Chinese biotech specializing in antibody-drug conjugates (ADCs), has opted not to move forward at this time with a plan to list on the Hong Kong Stock Exchange. 28 February 2025
Biotechnology
Enveda, a Colorado-based biotech, has received a $20 million investment from French pharma major Sanofi. 27 February 2025
Biotechnology
California-based biotech Eikon Therapeutics today announced the initial closing of a $350.7 million Series D financing. Since its founding in 2019, Eikon Therapeutics has privately raised in excess of $1.1 billion to support its mission of developing new medicines to address grievous illnesses, the company noted. 26 February 2025
Biotechnology
Ligand Pharmaceuticals has entered into a royalty financing agreement with Castle Creek Biosciences, providing $75 million to support the Phase III clinical trial of D-Fi (FCX-007), an investigational gene therapy for dystrophic epidermolysis bullosa (DEB). 26 February 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze